Ann: Shareholder Information Meetings, page-8

Thanks for the heads up.

I was only going by this; "The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result,
there are no plans for a near-term regulatory filing. There were no major safety or tolerability
concerns with CSL112."

I take note that CSL has also stated that in following up from the above statement; "Substantial work
remains to fully analyse and understand the complete data and then to determine any
development path ahead for this asset".

So technically, it's not dead and buried as you've pointed out. Either way, I've still been buying CSL and averaging up. But it is getting harder to buy the dips when it's been so range bound. I don't even know what the dips are these days?